TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

BACKGROUND: Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9–24 months duration, have poor efficacy and carry significant toxicity. A shorter, less toxic and more efficacious regimen would improve outcomes for people wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, Catherine, du Cros, Philipp, Fielding, Katherine, Gajewski, Suzanne, Kazounis, Emil, McHugh, Timothy D., Merle, Corinne, Motta, Ilaria, Moore, David A. J., Nyang’wa, Bern-Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190445/
https://www.ncbi.nlm.nih.gov/pubmed/35698158
http://dx.doi.org/10.1186/s13063-022-06331-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190445/
https://www.ncbi.nlm.nih.gov/pubmed/35698158
http://dx.doi.org/10.1186/s13063-022-06331-8

Ejemplares similares